Metagenomi Therapeutics, Inc. MGX
NASDAQ · United States · Health Technology
$1.08+0.01 (+1.42%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
These ratios divide the lines in the statements below by the current price; both inputs of every value are visible on this page. The P/E on the overview comes from the same calculation. P/E and P/S are left blank for loss-making companies or where revenue is not reported. Not investment advice.
| LTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | — | $25.21M | $52.30M | $44.76M |
| Revenue growth (YoY) | — | -51.8% | +16.8% | — |
| Operating expenses | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating Income | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating margin |
| MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| Pre-tax income | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Income tax | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Net Income | -$93.46M | -$87.87M | -$78.06M | -$68.26M |
| Net margin | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted EPS | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted shares | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| LTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash & equivalents | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Current Assets | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Assets | $173.70M | $221.10M | $324.60M | $364.84M |
| Total Current Liabilities | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Liabilities | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Equity | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| LTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash from Operations | -$85.49M | -$88.89M | -$109.07M | -$91.41M |
| Capital expenditure | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Free cash flow | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Investing | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Financing | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
Taken from the company's own 10-K and 10-Q filings via the SEC's XBRL data service. The "LTM" column is the last completed fiscal year plus the current year to date, minus the same period a year earlier. Lines a company tags with a non-standard label are left blank rather than filled with an approximation. Not investment advice.